FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110549062> ?p ?o ?g. }

• W2110549062 endingPage "144" @default.
• W2110549062 startingPage "138" @default.
• W2110549062 abstract "<h3>Objective</h3> Epithelial ovarian cancers (EOCs) are, although still treated as a single disease entity, often classified into type I tumors (low-grade serous, mucinous, endometrioid, clear cell) and type II tumors (high-grade serous, undifferentiated cancers, carcinosarcomas). The aim of our study was to determine the incidence, clinical relevance, and prognostic and predictive impact of somatic mutations in both types I and II EOCs. <h3>Methods</h3> Two hundred sixty-two evaluable, primary, high-risk stage I (grade 3, or aneuploid grade 1 or 2, or clear cell) and stage II-IV EOCs, collected at the University Hospitals Leuven and within the European Organisation for Research and Treatment of Cancer 55971 trial, were genotyped for hotspot mutations in KRAS (COSMIC [Catalogue of Somatic Mutations in Cancer] coverage >97%), BRAF (>94%), NRAS (>97%), PIK3CA (>79%), PTEN, FBXW7 (>57%), AKT2, AKT3, and FOXL2, using Sequenom MassARRAY. <h3>Results</h3> Of the 13% histopathologically classified type I tumors, 49% were KRAS or PIK3CA mutant versus only 2.9% in the type II tumors (87%). Mucinous subtypes harbored significantly more KRAS mutations than all nonmucinous tumors (50% vs 4%, <i>P</i> < 0.001). PIK3CA mutations were predominantly found in clear cell carcinomas (46.2%) and endometrioid carcinoma (20%) and were frequently associated with endometriosis. Moreover, low-grade serous tumors were more frequently KRAS or BRAF mutated (44%) than high-grade serous tumors (0.6%). KRAS or PIK3CA mutation did not correlate with progression-free survival or overall survival. Mutations in NRAS, PTEN, FBXW7, AKT2, AKT3, and FOXL2 were rare (<1%). <h3>Conclusions</h3> Somatic mutations are rare in type II EOCs, whereas type I EOCs contain distinct diseases with different driver mutations. In general, these tumors respond worse to standard paclitaxel carboplatin therapy. Clinical trials with molecular targeted therapy in the different subtypes of type I tumors are urgently needed using this theragnostic information." @default.
• W2110549062 created "2016-06-24" @default.
• W2110549062 creator A5014291043 @default.
• W2110549062 creator A5018721079 @default.
• W2110549062 creator A5020733605 @default.
• W2110549062 creator A5021753267 @default.
• W2110549062 creator A5031231823 @default.
• W2110549062 creator A5048414849 @default.
• W2110549062 creator A5058402654 @default.
• W2110549062 creator A5060002172 @default.
• W2110549062 date "2009-01-07" @default.
• W2110549062 modified "2023-10-15" @default.
• W2110549062 title "Nitric oxide production by the alveolar compartment of the lungs in cirrhotic patients" @default.
• W2110549062 cites W1970939696 @default.
• W2110549062 cites W1971929270 @default.
• W2110549062 cites W1979973939 @default.
• W2110549062 cites W1985885361 @default.
• W2110549062 cites W1990913823 @default.
• W2110549062 cites W1991875333 @default.
• W2110549062 cites W1997652125 @default.
• W2110549062 cites W1999785403 @default.
• W2110549062 cites W2005280335 @default.
• W2110549062 cites W2012356214 @default.
• W2110549062 cites W2033097591 @default.
• W2110549062 cites W2089856827 @default.
• W2110549062 cites W2098361750 @default.
• W2110549062 cites W2103675711 @default.
• W2110549062 cites W2103742362 @default.
• W2110549062 cites W2106021261 @default.
• W2110549062 cites W2112931524 @default.
• W2110549062 cites W2113260956 @default.
• W2110549062 cites W2121848682 @default.
• W2110549062 cites W2122230026 @default.
• W2110549062 cites W2133857292 @default.
• W2110549062 cites W2137118122 @default.
• W2110549062 cites W2141893452 @default.
• W2110549062 cites W2141922649 @default.
• W2110549062 cites W2143812614 @default.
• W2110549062 cites W2146965595 @default.
• W2110549062 cites W2160316261 @default.
• W2110549062 cites W2171435952 @default.
• W2110549062 cites W2408646082 @default.
• W2110549062 cites W297652177 @default.
• W2110549062 cites W47773688 @default.
• W2110549062 cites W2145705500 @default.
• W2110549062 doi "https://doi.org/10.1183/09031936.00148008" @default.
• W2110549062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19129270" @default.
• W2110549062 hasPublicationYear "2009" @default.
• W2110549062 type Work @default.
• W2110549062 sameAs 2110549062 @default.
• W2110549062 citedByCount "33" @default.
• W2110549062 countsByYear W21105490622012 @default.
• W2110549062 countsByYear W21105490622013 @default.
• W2110549062 countsByYear W21105490622014 @default.
• W2110549062 countsByYear W21105490622015 @default.
• W2110549062 countsByYear W21105490622016 @default.
• W2110549062 countsByYear W21105490622017 @default.
• W2110549062 countsByYear W21105490622018 @default.
• W2110549062 countsByYear W21105490622020 @default.
• W2110549062 countsByYear W21105490622023 @default.
• W2110549062 crossrefType "journal-article" @default.
• W2110549062 hasAuthorship W2110549062A5014291043 @default.
• W2110549062 hasAuthorship W2110549062A5018721079 @default.
• W2110549062 hasAuthorship W2110549062A5020733605 @default.
• W2110549062 hasAuthorship W2110549062A5021753267 @default.
• W2110549062 hasAuthorship W2110549062A5031231823 @default.
• W2110549062 hasAuthorship W2110549062A5048414849 @default.
• W2110549062 hasAuthorship W2110549062A5058402654 @default.
• W2110549062 hasAuthorship W2110549062A5060002172 @default.
• W2110549062 hasBestOaLocation W21105490621 @default.
• W2110549062 hasConcept C121608353 @default.
• W2110549062 hasConcept C126322002 @default.
• W2110549062 hasConcept C143998085 @default.
• W2110549062 hasConcept C150173356 @default.
• W2110549062 hasConcept C190283241 @default.
• W2110549062 hasConcept C21790070 @default.
• W2110549062 hasConcept C2777546739 @default.
• W2110549062 hasConcept C2777609662 @default.
• W2110549062 hasConcept C2778560582 @default.
• W2110549062 hasConcept C2781187634 @default.
• W2110549062 hasConcept C502942594 @default.
• W2110549062 hasConcept C526805850 @default.
• W2110549062 hasConcept C55493867 @default.
• W2110549062 hasConcept C71924100 @default.
• W2110549062 hasConcept C86554907 @default.
• W2110549062 hasConcept C86803240 @default.
• W2110549062 hasConceptScore W2110549062C121608353 @default.
• W2110549062 hasConceptScore W2110549062C126322002 @default.
• W2110549062 hasConceptScore W2110549062C143998085 @default.
• W2110549062 hasConceptScore W2110549062C150173356 @default.
• W2110549062 hasConceptScore W2110549062C190283241 @default.
• W2110549062 hasConceptScore W2110549062C21790070 @default.
• W2110549062 hasConceptScore W2110549062C2777546739 @default.
• W2110549062 hasConceptScore W2110549062C2777609662 @default.
• W2110549062 hasConceptScore W2110549062C2778560582 @default.
• W2110549062 hasConceptScore W2110549062C2781187634 @default.
• W2110549062 hasConceptScore W2110549062C502942594 @default.
• W2110549062 hasConceptScore W2110549062C526805850 @default.

• next